Titan Pharmaceuticals (NASDAQ:TTNP) Now Covered by StockNews.com

Stock analysts at StockNews.com assumed coverage on shares of Titan Pharmaceuticals (NASDAQ:TTNP) in a report issued on Monday. The firm set a “sell” rating on the specialty pharmaceutical company’s stock.

Titan Pharmaceuticals Price Performance

TTNP stock opened at $7.26 on Monday. Titan Pharmaceuticals has a twelve month low of $5.00 and a twelve month high of $16.60. The business has a 50 day simple moving average of $7.27 and a 200-day simple moving average of $7.26.

Institutional Investors Weigh In On Titan Pharmaceuticals

Hedge funds have recently modified their holdings of the stock. State Street Corp acquired a new stake in shares of Titan Pharmaceuticals during the third quarter worth $41,000. Virtu Financial LLC purchased a new position in Titan Pharmaceuticals in the second quarter worth $35,000. Millennium Management LLC raised its position in Titan Pharmaceuticals by 516.8% in the second quarter. Millennium Management LLC now owns 63,106 shares of the specialty pharmaceutical company’s stock worth $35,000 after acquiring an additional 52,874 shares in the last quarter. Finally, Renaissance Technologies LLC raised its position in Titan Pharmaceuticals by 559.3% in the second quarter. Renaissance Technologies LLC now owns 240,710 shares of the specialty pharmaceutical company’s stock worth $135,000 after acquiring an additional 204,200 shares in the last quarter. 31.49% of the stock is owned by institutional investors and hedge funds.

About Titan Pharmaceuticals

Titan Pharmaceuticals, Inc, a pharmaceutical company, develops therapeutics for the treatment of chronic diseases. It develops products based on ProNeura, a proprietary long-term drug delivery platform. The company offers Probuphine implant for the maintenance treatment of opioid use disorder in clinically stable patients in the United States, Canada, and the European Union.